Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort

Fig. 3

A-L Drug survival in the overall population and after their subdivision in two groups, according to the DMARD treatment line (naïve vs non-naïve patients) (A), use of combined csDMARDs (no csDMARDs vs. csDMARDs) (B), gender (male vs. female) (C), age (< 60 years patients vs < 60 years patients) (D), BMI (overweight vs. normal weight) (E), comorbidities (patients without comorbidities vs patients with comorbidities (F), disease phenotype (mono/oligoarthritis vs. polyarthritis (G), no axial disease vs. axial disease (H), no enthesitis vs. enthesitis (I), and no psoriasis vs. psoriasis (L)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us